Израел - иврит - Ministry of Health

teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

Израел - иврит - Ministry of Health

teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

Израел - иврит - Ministry of Health

rekah pharmaceutical industry ltd, israel - benzocaine; bismuth subgallate; zinc oxide - פתילות - bismuth subgallate 180 mg; zinc oxide 120 mg; benzocaine 15 mg - bismuth preparations, combinations - bismuth preparations, combinations - for the relief of hemorrhoids.

Израел - иврит - Ministry of Health

glaxo smith kline (israel) ltd - a/california/7/2009 (h1n1) 15 mcg / 0.5 ml; a/victoria/361/2011 (h3n2) 15 mcg / 0.5 ml - suspension for injection - influenza, live attenuated - prophylaxis of influenza, especially those who run an increased risk of associated complications. fluarix is indicated in adults and children from 6 months of age.

Израел - иврит - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Израел - иврит - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 10 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Израел - иврит - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 2.5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Израел - иврит - Ministry of Health

megapharm ltd - anethole; borneol; camphene; cineole; fenchone; pinene alfa; pinene beta - קפסולות - camphene 15 mg; cineole 3 mg; fenchone 4 mg; borneol 10 mg; anethole 4 mg; pinene beta 6.2 mg; pinene alfa 24.8 mg - urinary concrement solvents - as an adjuvant in infections of kidenys and urinary tract.

Израел - иврит - Ministry of Health

איה נטורל בעמ - רחצת הגוף

Израел - иврит - Ministry of Health

ש.שוורץ באר שבע בעמ - צמצום קמטים וקמטוטים